These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 9704015)

  • 1. The HIV-inactivating protein, cyanovirin-N, does not block gp120-mediated virus-to-cell binding.
    Mariner JM; McMahon JB; O'Keefe BR; Nagashima K; Boyd MR
    Biochem Biophys Res Commun; 1998 Jul; 248(3):841-5. PubMed ID: 9704015
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cyanovirin-N, a potent human immunodeficiency virus-inactivating protein, blocks both CD4-dependent and CD4-independent binding of soluble gp120 (sgp120) to target cells, inhibits sCD4-induced binding of sgp120 to cell-associated CXCR4, and dissociates bound sgp120 from target cells.
    Mori T; Boyd MR
    Antimicrob Agents Chemother; 2001 Mar; 45(3):664-72. PubMed ID: 11181340
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective interactions of the human immunodeficiency virus-inactivating protein cyanovirin-N with high-mannose oligosaccharides on gp120 and other glycoproteins.
    Shenoy SR; O'Keefe BR; Bolmstedt AJ; Cartner LK; Boyd MR
    J Pharmacol Exp Ther; 2001 May; 297(2):704-10. PubMed ID: 11303061
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dissecting carbohydrate-Cyanovirin-N binding by structure-guided mutagenesis: functional implications for viral entry inhibition.
    Barrientos LG; Matei E; Lasala F; Delgado R; Gronenborn AM
    Protein Eng Des Sel; 2006 Dec; 19(12):525-35. PubMed ID: 17012344
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Properties of cyanovirin-N (CV-N): inactivation of HIV-1 by sessile cyanovirin-N (sCV-N).
    Gandhi MJ; Boyd MR; Yi L; Yang GG; Vyas GN
    Dev Biol (Basel); 2000; 102():141-8. PubMed ID: 10794101
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIV requires multiple gp120 molecules for CD4-mediated infection.
    Layne SP; Merges MJ; Dembo M; Spouge JL; Nara PL
    Nature; 1990 Jul; 346(6281):277-9. PubMed ID: 2374593
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of sequence requirements for biological activity of cyanovirin-N, a potent HIV (human immunodeficiency virus)-inactivating protein.
    Mori T; Shoemaker RH; Gulakowski RJ; Krepps BL; McMahon JB; Gustafson KR; Pannell LK; Boyd MR
    Biochem Biophys Res Commun; 1997 Sep; 238(1):218-22. PubMed ID: 9299482
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiple antiviral activities of cyanovirin-N: blocking of human immunodeficiency virus type 1 gp120 interaction with CD4 and coreceptor and inhibition of diverse enveloped viruses.
    Dey B; Lerner DL; Lusso P; Boyd MR; Elder JH; Berger EA
    J Virol; 2000 May; 74(10):4562-9. PubMed ID: 10775592
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Specific CD4 down-modulating compounds with potent anti-HIV activity.
    Vermeire K; Schols D
    J Leukoc Biol; 2003 Nov; 74(5):667-75. PubMed ID: 12960237
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cyanovirin-N potently inhibits human immunodeficiency virus type 1 infection in cellular and cervical explant models.
    Buffa V; Stieh D; Mamhood N; Hu Q; Fletcher P; Shattock RJ
    J Gen Virol; 2009 Jan; 90(Pt 1):234-43. PubMed ID: 19088294
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of N-phenyl-N'-(2,2,6,6-tetramethyl-piperidin-4-yl)-oxalamides as a new class of HIV-1 entry inhibitors that prevent gp120 binding to CD4.
    Zhao Q; Ma L; Jiang S; Lu H; Liu S; He Y; Strick N; Neamati N; Debnath AK
    Virology; 2005 Sep; 339(2):213-25. PubMed ID: 15996703
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Soluble gC1q-R/p33, a cell protein that binds to the globular "heads" of C1q, effectively inhibits the growth of HIV-1 strains in cell cultures.
    Szabó J; Cervenák L; Tóth FD; Prohászka Z; Horváth L; Kerekes K; Beck Z; Bácsi A; Erdei A; Peerschke EI; Füst G; Ghebrehiwet B
    Clin Immunol; 2001 May; 99(2):222-31. PubMed ID: 11318594
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Resistance of human immunodeficiency virus type 1 to the high-mannose binding agents cyanovirin N and concanavalin A.
    Witvrouw M; Fikkert V; Hantson A; Pannecouque C; O'keefe BR; McMahon J; Stamatatos L; de Clercq E; Bolmstedt A
    J Virol; 2005 Jun; 79(12):7777-84. PubMed ID: 15919930
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An anti-human immunodeficiency virus multiple antigen peptide encompassing the cleavage region of the env precursor interferes with membrane fusion at a post-CD4 binding step.
    Barbouche R; Decroly E; Kieny MP; Fenouillet E
    Virology; 2000 Jul; 273(1):169-77. PubMed ID: 10891419
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recombinant production of cyanovirin-N, a potent human immunodeficiency virus-inactivating protein derived from a cultured cyanobacterium.
    Mori T; Gustafson KR; Pannell LK; Shoemaker RH; Wu L; McMahon JB; Boyd MR
    Protein Expr Purif; 1998 Mar; 12(2):151-8. PubMed ID: 9518455
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cyanovirin-N binds to gp120 to interfere with CD4-dependent human immunodeficiency virus type 1 virion binding, fusion, and infectivity but does not affect the CD4 binding site on gp120 or soluble CD4-induced conformational changes in gp120.
    Esser MT; Mori T; Mondor I; Sattentau QJ; Dey B; Berger EA; Boyd MR; Lifson JD
    J Virol; 1999 May; 73(5):4360-71. PubMed ID: 10196334
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification and characterization of peptides that bind to cyanovirin-N, a potent human immunodeficiency virus-inactivating protein.
    Han Z; Simpson JT; Fivash MJ; Fisher R; Mori T
    Peptides; 2004 Apr; 25(4):551-61. PubMed ID: 15165709
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential effects of a hydrophobic tripeptide on human immunodeficiency virus type 1 (HIV-1)-induced syncytium formation and viral infectivity.
    Konopka K; Pretzer E; Düzgünes N
    Biochem Biophys Res Commun; 1995 Mar; 208(1):75-81. PubMed ID: 7887968
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of HIV-1 replication and infectivity by expression of a fusion protein, VPR-anti-integrase single-chain variable fragment (SFv): intravirion molecular therapies.
    BouHamdan M; Kulkosky J; Duan LX; Pomerantz RJ
    J Hum Virol; 2000; 3(1):6-15. PubMed ID: 10774802
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Critical role of Arg59 in the high-affinity gp120-binding region of CD4 for human immunodeficiency virus type 1 infection.
    Fontenot D; Jones JK; Hossain MM; Nehete PN; Vela EM; Dwyer VA; Jagannadha Sastry K
    Virology; 2007 Jun; 363(1):69-78. PubMed ID: 17320923
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.